Decreasing hepatic glucose production

The term “decreasing hepatic glucose production” refers to a therapeutic approach aimed at reducing the liver’s output of glucose, primarily via inhibition of gluconeogenesis or glycogenolysis. In diabetes, especially type 2, hepatic glucose production is often abnormally elevated due to increased gluconeogenesis, driven by insulin resistance and dysregulated hormone signaling (e.g., increased glucagon)[2][4][5]. Key molecular targets in this process include gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), as well as hormonal pathways (insulin, glucagon) and regulatory transcription factors. Drugs such as metformin lower blood glucose by suppressing hepatic glucose production, chiefly by reducing the activity and expression of these enzymes, activating AMPK, and modulating relevant signaling pathways[2][4][5][6]. Safety concerns exist, especially in patients with hepatic insufficiency or when used in combination with other agents. Key points: - This is *not* a molecular entity or receptor, but a process or strategy. - The underlying molecular targets include enzymes (PEPCK, G6Pase, glucokinase), nuclear receptors, and signaling proteins modulated by hormone and drug action[1][2][3][4][5][6]. - It is a high-priority therapeutic goal in diabetes and related metabolic disorders[2][4].

Other names

Decreasing hepatic gluconeogenesissuppression of hepatic glucose outputinhibition of hepatic gluconeogenesisinhibition of liver glucose production

Inhibition of hepatic gluconeogenesis via AMPK activation (metformin)[2][4][5]; Suppression of gluconeogenic enzyme transcription (PEPCK, G6Pase)[2][3][5]; Modulation of hormonal signaling (e.g., reducing glucagon stimulation, increasing insulin signaling)[2][4][5]